Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (Weighted Average) (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $43.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 547.69% year-over-year to $43.3 million, compared with a TTM value of $43.3 million through Sep 2025, up 547.69%, and an annual FY2024 reading of $201.1 million, up 13.08% over the prior year.
  • Shares Outstanding (Weighted Average) was $43.3 million for Q3 2025 at X4 Pharmaceuticals, up from $7.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $201.1 million in Q4 2024 and bottomed at $6.7 million in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $66.7 million, with a median of $33.7 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 96.61% in 2024, then surged 547.69% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $25.7 million in 2021, then skyrocketed by 146.71% to $63.5 million in 2022, then skyrocketed by 179.91% to $177.8 million in 2023, then increased by 13.08% to $201.1 million in 2024, then plummeted by 78.48% to $43.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for XFOR at $43.3 million in Q3 2025, $7.4 million in Q2 2025, and $6.8 million in Q1 2025.